• Facebook

China Healthcare Investor Forum 2017

中文版请点击这里 The China Healthcare Investor Forum 2017, hosted by China Money Network, will feature the nation's brightest and most successful healthcare investors discussing key opportunities and challenges in one of the world's hottest investment sectors. Register now to join leading deal makers from KPCB, CDH Investments, C-Bridge Capital, Lilly Asia Ventures and OrbiMed for an intimate and informative panel discussion and open Q&A. Then network with other attendees from top Chinese investment firms and healthcare company executives. Limited seats available. Click Here For Payment Methods In Mainland China EVENT DETAILS: Date: Sep 19, 2017 Time: 16:30-18:30pm Location:50/F, Shanghai World Financial Center, 100 Century Avenue, Pudong, Shanghai Language: English Healthcare has without doubt been one of the hottest investment sectors in China over the past decade. From 2010 to 2016, venture capital and private equity investment deal volume and total deal value grew 33.7% and 89% annually on average, respectively. With China being the world's most populous nation, the addressable market is gigantic. The country's healthcare industry is expected to reach RMB16 trillion (US$2.3 trillion) in size by 2030. From healthcare services, to medical equipment and pharmaceuticals, there is a wide gap between supply and demand for high quality products and …

Chinese RMB Fund QS Capital Raises $14M Debut Fund

A Chinese RMB venture capital firm QS Capital has raised RMB100 million (US$14 million) for its debut fund, which will make early-stage investments on biotechnology, medical equipment and new consumer themes in China, it announced today.

Tsinghua's Venture Arm Leads $18M Round In Cancer Diagnosis Start-Up

Beijing-based THG Ventures, a venture capital arm of Tsinghua Holdings, has led a RMB128 million (US$18 million) series B round in Genecast, a Beijing-based cancer diagnosis and therapy company. Suzhou-based Cowin Venture, BW Ventures, Loyal Valley Innovation Capital, and Yahui Precise Medical Care Fund also participated in the round. Founded in 2014, Genecast provides tumor DNA testing and gene-based medicine guidance, targeting lung cancer, colon cancer, liver cancer and breast cancer. Its products have been used in over 200 hospitals in China, and the company has partnered with a number of hospitals and universities including the University of Pennsylvania medical school, Peking Union Medical College Hospital and Beijing Cancer Hospital. The company previously raised an undisclosed angel round from Cowin Venture, and RMB20 million (US$3 million) in a series A round from private equity firm Yifuze Equity Investment Fund. Genecast plans to use the proceeds to focus on research and clinical trials, as well as expanding distribution channels.

Baidu Closes Mobile Healthcare Unit To Focus On AI-Enabled Services

Chinese Internet giant Baidu Inc. has shut down its two-year-old mobile healthcare business unit in order to focus on artificial intelligence-enabled healthcare services as part of its on-going strategic restructuring, according to news report published by Tencent Technology.

Temasek To Invest $800M In Alphabet's Healthcare Unit Verily

Singapore's state investment fund Temasek Holdings has agreed to invest US$800 million in Verily Life Sciences LLC, a healthcare subsidiary of Alphabet Inc. Following the deal, Temasek will receive a minority stake in the unit and help it expand outside of the U.S., particularly in Asia.

Sanpower Group, CITIC Bank Launch $2.9B Healthcare M&A Fund

Sanpower Group and China CITIC Bank said they would establish a healthcare industry M&A fund with targeted fundraising of RMB20 billion (US$2.9 billion) to support Sanpower's strategic push into healthcare, the firms announced yesterday.

China Healthcare Investment Remains Vibrant Despite Slower Deal Pace

Venture capital and private equity investments in China's healthcare industry slowed in 2016, amid an overall cooling of the broader venture market. But despite the slowdown, healthcare remained relatively vibrant with both deal volume and deal value ranked at the second highest level since 2011, and following a feverish 2015. Venture and private equity firms invested in the sector managed to achieve a slight increase in average book value return from a year earlier.

C-Bridge's Fu Wei Aims To Profit By Transferring Pharma Tech To China

C-Bridge Capital, a Shanghai-based private equity firm focused on China's healthcare sector, hopes to profit handsomely by bringing better drug know-how from developed markets to the underdeveloped Chinese pharmaceutical industry. Headed by finance veteran Fu Wei, the US$700 million-under-management firm led a follow-on US$100 million round in Chinese pharmaceutical start-up Ascletis earlier this month. Ascletis has licensed and conducted clinical trail on a hepatitis C treatment drug developed by an American company, and is launching the drug in China during the first half of this year. The sheer scale of the Chinese market makes the investment attractive, says Fu, a University of Chicago Booth School of Business graduate. With 40 million hepatitis C patients in China, compared to just four million in the U.S.,  he is confident that the drug will hit it big and bring a lucrative return on his investment. C-Bridge Capital is also looking at other areas such as hepatitis B, which is an even bigger market, and also lung cancer, which has seen a dramatic increase in China due to an aging population of smokers and the effects of high pollution levels in Chinese cities. Fu also sees the need for widespread consolidation in the Chinese pharma and …

Matrix China Leads $14M Round In Precision Medicine Start-Up TopGene

Matrix Partners China has led a series A funding round worth over RMB100 million (US$14 million) in TopGene, a Guangzhou-based DNA testing and precision medicine start-up. Founded in 2014, TopGene focuses on DNA testing and screening of genes connected to breast cancer, colorectal cancer and lung cancer. It also operates a cancer precision medicine center in China, and plans to open dozens more in the next few years. "The founding team of TopGene has strong medical and biology experiences. The company has grown rapidly in the past two years with operations covering 30 provinces in the Greater China region," said Xue Chuansheng, founding managing partner at Matrix China. In China, the number of female cancer patients has been growing at 2.2% annually. TopGene's DNA testing of BRCA mutation, for example, has great growth potential as it could be used to predict breast and ovary cancer, according to the company. The company plans to use the proceeds on mining massive amount of data to better conduct diagnosis, prevention and treatment of different types of cancer.